Publications

Lin C, Pulliam TL, Han JJ, Xu J, Recio CV, Wilkenfeld SR, Shi Y, Kushwaha M, Bench S, Ruiz E, Senthilkumar S, Dileep J, Shepherd PDA, Navone NM, Klekers AR, Whitley EM, Ittmann MM, Eberlin LS, Wang W, Frigo DE. Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer. Cell Rep. 2025. Jun 6;44(6):115792. [Epub ahead of print]. PMID: 40483692.

Chen F, Li H, Wang Y, Tang X, Lin K, Li Q, Meng C, Shi W, Leo J, Liang X, Zhang J, Van V, Mahmud I, Wei B, Lorenzi PL, Raso MG, Aparicio A, Lu Y, Frigo DE, Gan B, Zhao D. CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumors. Nat Cancer. 2025 May;6(5):854-873. Epub 2025 May 13. PMID: 40360905.

Fang A, Frigo DE, Hahn A, Razouki Z, Hwang J, Koutroumpakis E, Lawen T, Smith M, Hamilton-Reeves J, DiGiovanni J, Higgason N, Garcia RS, Chapin BF, Pettaway C, Chery L, Troncoso P, Logothetis C, Daniel CR, Wei P, Gregg JR. GLP-1 Agonist Use Among Men with Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical Trials. Urology. 2025 May 8:S0090-4295(25)00426-1. [Epub ahead of print]. PMID: 40348027.

Koutroumpakis E, Venkatesh N, Aparicio A, Song J, Panaretakis T, Deswal A, Logothetis CJ, Frigo DE, Hahn AW. Leptin Levels are Associated with Coronary Artery Calcification in Patients with Advanced Prostate Cancer. Oncologist. 2024 Nov 18:oyae308. [Epub ahead of print]. PMID: 39557398.

Venkatesh N, Tidwell RS, Yu Y, Aparicio A, Zurita AJ, Subudhi SK, Siddiqui BA, Mukhida SS, Gregg JR, Corn PG, Koutroumpakis E, McQuade JL, Frigo DE, Pilie PG, Huff CD, Logothetis CJ, Hahn AW. Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer. 2024 Oct 29;31(12):e240195. PMID: 39324992.

Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis. 2024 Jul 17. (online ahead of print). PMID: 39019979.

Frigo DE. Diet and Tumor Genetics Conspire to Promote Prostate Cancer Metabolism and Shape the Tumor Microenvironment. Cancer Res. 2024 Jun 4;84(11):1742-1744. PMID: 38831750.

Cao PHA, Dominic A, Lujan FE, Senthilkumar S, Bhattacharya PK, Frigo DE*, Subramani E*. Unlocking ferroptosis in prostate cancer— the road to novel therapies and imaging markers. Nat Rev Urol. 2024 Oct;21(10):615-637. PMID: 38627553. *co-corresponding authors

Awad D, Cao PHA, Pulliam TL, Spradlin M, Subramani E, Tellman TV, Ribeiro CF, Muzzioli R, Jewell BE, Pakula H, Ackroyd JJ, Murray MM, Han JJ, Leng M, Jain A, Piyarathna B, Liu J, Song X, Zhang J, Klekers AR, Drake JM, Ittmann MM, Coarfa C, Piwnica-Worms D, Farach-Carson MC, Loda M, Eberlin LS, Frigo DE. Adipose triglyceride lipase is a therapeutic target in advanced prostate cancer that promotes metabolic plasticity. Cancer Res. 2024 Mar 4;84(5):703-724. PMID: 38038968.

Subramani E, Dominic A, Bhattacharya PK, Frigo DE, Bederman I, Vaziri-Gohar A. Editorial: Metabolic regulation under oxidative stress in cancer. Front Oncol. 2023 Sep 12;13:1286086. doi: 10.3389/fonc.2023.1286086. PMID: 37771445.

Hasterok S, Scott TG, Roller DG, Spencer A, Dutta AB, Sathyan KM, Frigo DE, Guertin MJ, Gioeli D. The androgen receptor does not directly regulate the transcription of DNA damage response genes. Mol Cancer Res. 2023 Dec 1;21(12):1329-1341. PMID: 37698543.

Xu W, Qadir MMF, Nasteska D, Mota de Sa P, Gorvin CM, Blandino-Rosano M, Evans CR, Ashford FB, Bitsi S, Fan J, Bhondeley M, Song K, Sure VN, Schiffer L, Beatty W, Wyatt R, Frigo DE, Liu X, Katakam PV, Arlt W, Buck J, Levin LR, Hu T, Kolls J, Burant CF, Tomas A, Bernal-Mizrachi E, Hodson DJ, and Mauvais-Jarvis F. Architecture of androgen receptor pathways amplifying glucagon-like peptide-1 insulinotropic action in male pancreatic β-cells. Cell Rep. 2023 May 30;42(5):112529. PMID: 37200193.

Hahn AW, Siddiqui BA, Leo J, Dondossola E, Basham KJ, Miranti CK, Frigo DE. Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate Cancer. Endocrinology. 2023 Apr 17;164(6):bqad078. doi: 10.1210/endocr/bqad078. PMID: 37192413.

Leo J, Dondossola E, Basham KJ, Wilson NR, Alhalabi O, Gao J, Kurnit KC, White MG, McQuade JL, Westin SN, Wellberg EA, Frigo DE. Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer. Endocrinology. 2023 Apr 17;164(6):bqad071. doi: 10.1210/endocr/bqad071. PMID: 37154098.

Wells C, Liang Y, Pulliam TL, Lin C, Awad D, Eduful B, O’Byrne S, Hossain MA, Catta-Preta CMC, Ramos PZ, Gileadi O, Gileadi C, Couñago RM, Stork B, Langendorf CG, Nay K, Oakhill J, Mukherjee D, Racioppi L, Means AR, York B, McDonnell DP, Scott JW, Frigo DE, Drewry DH. SGC-CAMKK2-1: A chemical probe for CAMKK2. Cells 12(2): 287, 2023. PMID: 36672221.

Mossa F, Robesti D, Sumankalai R, Corey E, Titus M, Kang Y, Zhang J, Briganti A, Montorsi F, Vellano CP, Marszaleck JR, Frigo DE, Logothetis CJ, Gujral TS, Dondossola E. Subtype and site specific-induced metabolic vulnerabilities in prostate cancer. Mol Cancer Res 21(1): 51-61, 2023. PMID: 36112348.

Sakellakis MJ, Hahn AW, Ramachandran S, Zhang M, Hoang A, Song JH, Liu J, Wang F, Basu HS, Sheperd P, Wang X, Frigo DE, Lin SH, Panaretakis T, Zhang J, Navone NM, Troncoso P, Logothetis CJ, Titus MA. Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. Prostate Cancer Prostatic Dis 26(4):751-758, 2023. PMID: 36100698.

Pulliam TL, Awad D, Han JJ, Murray MM, Ackroyd JJ, Goli P, Oakhill JS, Scott JW, Ittmann MM, Frigo DE. Systemic Ablation of Camkk2 Impairs Metastatic Colonization and Improves Insulin Sensitivity in TRAMP Mice: Evidence for Cancer Cell-Extrinsic CAMKK2 Functions in Prostate Cancer. Cells 11(12): 1890, 2022. PMID: 35741020.

Pulliam TL, Goli P, Awad D, Lin C, Wilkenfeld SR, Frigo DE. Regulation and Role of CAMKK2 in Prostate Cancer. Nat Rev Urol 19(6):367-380, 2022. PMID: 35474107.

Frigo DE, Bondesson M, Williams C. Nuclear Receptors: From Molecular Mechanisms to Therapeutics. Essays Biochem 65(6):847-856, 2021. PMID: 34825698.

Eduful B, O'Byrne S, Temme L, Asquith CRM, Liang Y, Picado A, Pilotte J, Wells C, Zuercher WJ, Catta-Preta C, Ramos PZ, Santiago A, Counago R, Langendorf CG, Nay K, Oakhill JS, Pulliam TL, Lin C, Awad D, Willson TM, Frigo DE, Scott JW, Drewry DH. Hinge Binder Scaffold Hopping Identifies Potent Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2) Inhibitor Chemotypes. J Med Chem 64(15):10849-10877, 2021. PMID: 34264658.

Barton M, Frigo DE, Madak-Erdogan Z, Mauvais-Jarvis F, Prossnitz ER. Steroid Hormones and Receptors in Health and Disease: A Research Conference Co-Organized by FASEB and the International Committee on Rapid Responses to Steroid Hormones (RRSH), May 25-27, 2021. FASEB J 35(11):e21858, 2021. PMID: 34634152.

Shatnawi A, Abu Rabe DI, Frigo DE. Roles of the tumor suppressor inhibitor of growth family member 4 (ING4) in cancer. Adv Cancer Res 152:225-262, 2021. PMID: 34353439.

Lin C, Blessing AM, Pulliam TL, Shi Y, Wilkenfeld SR, Han JJ, Murray MM, Pham AH, Duong K, Brun SN, Shaw RJ, Ittmann MM, Frigo DE. Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling. Oncogene 40(9):1690-1705, 2021. PMID: 33531625.

Subramani E, Frigo DE. Mitochondria in Metabolic Syndrome, Reproduction and Transgenerational Inheritance—Ongoing Debates and Emerging Links. Endocrinology 162(1):bqaa182, 2021. PMID: 33275660.

Chen R, Liang X, Murray MM, Karasik E, Han JJ, Zhu M, Foster BA*, Frigo DE*, Wang G*. A simple quantitative PCR assay to determine TRAMP transgene zygosity. Prostate Cancer Prostatic Dis 24(2):358-361, 2021. PMID: 32895469. *co-corresponding authors

Dahl HC, Kanchwala M, Thomas-Jardin SE, Sandhu A, Kanumuri P, Xing C, Lin C, Frigo DE, Delk NA. Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence. PLoS One 15(12):e0242970, 2020. PMID: 33326447.